# Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study

> **NCT06868030** · — · NOT_YET_RECRUITING · sponsor: **First Hospital of China Medical University** · enrollment: 120 (estimated)

## Conditions studied

- Alzheimer's Disease
- MCI-AD, Early Stage Alzheimer's Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06868030
- **Lead sponsor:** First Hospital of China Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06868030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06868030, "Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06868030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*